A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Protocol No
MERCK-MK-7339-010
Principal Investigator
Deepak Kilari
Phase
III
Summary
The purpose of this study is to: - See if Pembrolizumab in combination with Olaparib helps patients live longer - Test the safety of Pembrolizumab (MK-3475) in combination with Olaparib when compared to standard of care hormonal medication - See how well Pembrolizumab in combination with Olaparib works when compared to standard of care hormonal medication - See if Pembrolizumab in combination with Olaparib helps patients have a better quality of life Pembrolizumab has been approved for patients with certain types of cancer; however, it has not been approved for your type of cancer. Olaparib has been approved for patients with certain types of cancers; however, it has not been approved for your type of cancer. The drugs being used in this study (Abiraterone Acetate, Prednisone, and Enzalutamide) are standard treatments for patients with your type of cancer. Getting Pembrolizumab in combination with Olaparib for your type of prostate cancer is considered experimental.
Description
Phase 3 Study of Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in mCRPC
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: